This HTML5 document contains 120 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00618/identifier/chebi/
n8http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB00618/identifier/wikipedia/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00618/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n23http://www.drugs.com/cdi/
n19http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00618/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00618/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00618/identifier/national-drug-code-directory/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00618
rdf:type
n3:Drug
n3:description
A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. [PubChem]
n3:dosage
n6:271B5743-363D-11E5-9242-09173F13E4C5 n6:271B5744-363D-11E5-9242-09173F13E4C5 n6:271B5745-363D-11E5-9242-09173F13E4C5 n6:271B5746-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# De Troyer A, Demanet JC: Correction of antidiuresis by demeclocycline. N Engl J Med. 1975 Oct 30;293(18):915-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/170519
n3:group
approved
n3:halfLife
10-17 hours
n3:indication
Used primarily to treat Lyme disease, acne, and bronchitis. Also indicated (but rarely used) to treat urinary tract infections, gum disease, malaria, and other bacterial infections such as gonorrhea and chlamydia. One of its other registered uses is the treatment of hyponatremia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.
n3:manufacturer
n4:271B572C-363D-11E5-9242-09173F13E4C5 n4:271B5729-363D-11E5-9242-09173F13E4C5 n4:271B572A-363D-11E5-9242-09173F13E4C5 n4:271B5727-363D-11E5-9242-09173F13E4C5 n4:271B5728-363D-11E5-9242-09173F13E4C5 n4:271B573D-363D-11E5-9242-09173F13E4C5 n4:271B573E-363D-11E5-9242-09173F13E4C5 n4:271B573B-363D-11E5-9242-09173F13E4C5 n4:271B573C-363D-11E5-9242-09173F13E4C5 n4:271B5739-363D-11E5-9242-09173F13E4C5 n4:271B573A-363D-11E5-9242-09173F13E4C5 n4:271B5737-363D-11E5-9242-09173F13E4C5 n4:271B5738-363D-11E5-9242-09173F13E4C5 n4:271B5725-363D-11E5-9242-09173F13E4C5 n4:271B5726-363D-11E5-9242-09173F13E4C5 n4:271B5724-363D-11E5-9242-09173F13E4C5 n4:271B5735-363D-11E5-9242-09173F13E4C5 n4:271B5736-363D-11E5-9242-09173F13E4C5 n4:271B5733-363D-11E5-9242-09173F13E4C5 n4:271B5734-363D-11E5-9242-09173F13E4C5 n4:271B5731-363D-11E5-9242-09173F13E4C5 n4:271B5732-363D-11E5-9242-09173F13E4C5 n4:271B572F-363D-11E5-9242-09173F13E4C5 n4:271B5730-363D-11E5-9242-09173F13E4C5 n4:271B572D-363D-11E5-9242-09173F13E4C5 n4:271B572E-363D-11E5-9242-09173F13E4C5 n4:271B572B-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00618 n13:DB00618
dcterms:title
Demeclocycline
adms:identifier
n15:61748-115-01 n16:D00290 n17:4392 n18:DB00618 n25:PA164745513 n26:Demeclocycline
n3:mechanismOfAction
Demeclocycline inhibits cell growth by inhibiting translation. It binds (reversibly) to the 30S and 50S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome, which impairs protein synthesis by bacteria. The binding is reversible in nature. The use in SIADH actually relies on a side-effect of tetracycline antibiotics; many may cause diabetes insipidus (dehydration due to the inability to concentrate urine). It is not completely understood why demeclocycline impairs the action of antidiuretic hormone, but it is thought that it blocks the binding of the hormone to its receptor.
n3:packager
n4:271B5719-363D-11E5-9242-09173F13E4C5 n4:271B571A-363D-11E5-9242-09173F13E4C5 n4:271B571D-363D-11E5-9242-09173F13E4C5 n4:271B571E-363D-11E5-9242-09173F13E4C5 n4:271B571B-363D-11E5-9242-09173F13E4C5 n4:271B571C-363D-11E5-9242-09173F13E4C5 n4:271B5721-363D-11E5-9242-09173F13E4C5 n4:271B5722-363D-11E5-9242-09173F13E4C5 n4:271B571F-363D-11E5-9242-09173F13E4C5 n4:271B5720-363D-11E5-9242-09173F13E4C5 n4:271B5723-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Demeclocycline hydrochloride, like other tetracyclines, is concentrated in the liver and excreted into the bile where it is found in much higher concentrations than in the blood. Following a single 150 mg dose of demeclocycline hydrochloride in normal volunteers, 44% (n = 8) was excreted in urine and 13% and 46%, respectively, were excreted in feces in two patients within 96 hours as active drug.
n3:synonym
7-Chloro-6-demethyltetracycline Demethylchlortetracycline Demeclociclina DMCT Demethylchlortetracyclin [4S-(4alpha,4Aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide Demeclocyclinum 6-Demethyl-7-chlorotetracycline DMCTC Demeclocycline
n3:toxicity
Oral, rat: LD<sub>50</sub> = 2372 mg/kg
n11:hasAHFSCode
n22:08-12-24
n3:foodInteraction
Avoid milk and multivalent ions. Take on an empty stomach.
n3:proteinBinding
41-50%
n3:salt
n3:synthesisReference
McCormick, J.R.D., Hirsch, U., Jensen, E.R. and Sjolander, N.O.; U.S. Patent 2,878,289; March 17, 1959; assigned to American Cyanamid Company. Szumski, S.A.; U.S. Patent 3,012,946; December 12,1961; assigned to American Cyanamid Company. Goodman, J.J. and Matrishin, M.; U.S. Patent 3,019,172; assigned to American Cyanamid Company. Goodman, J.J.; U.S. Patent 3,050,446; August 21, 1962; assigned to American Cyanamid Company. Neidleman, S. L.; US. Patent 3,154,476; October 27,1964; assigned to Olin Mathieson Chemical Corporation.
n9:hasConcept
n10:M0005801
foaf:page
n21:demeclocycline.htm n23:demeclocycline.html
n3:IUPAC-Name
n19:271B574B-363D-11E5-9242-09173F13E4C5
n3:InChI
n19:271B5751-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n19:271B5750-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n19:271B574D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n19:271B574E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n19:271B574F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n19:271B5749-363D-11E5-9242-09173F13E4C5 n19:271B5761-363D-11E5-9242-09173F13E4C5
n3:logP
n19:271B5747-363D-11E5-9242-09173F13E4C5 n19:271B574A-363D-11E5-9242-09173F13E4C5 n19:271B5763-363D-11E5-9242-09173F13E4C5
n3:logS
n19:271B5748-363D-11E5-9242-09173F13E4C5 n19:271B5764-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:J01AA01 n12:D06AA01
n3:H-Bond-Acceptor-Count
n19:271B5757-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n19:271B5758-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n19:271B5752-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n19:271B5753-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n19:271B5755-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n19:271B5754-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n19:271B5756-363D-11E5-9242-09173F13E4C5
n3:absorption
Tetracyclines are readily absorbed.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
127-33-3
n3:category
n3:clearance
* Renal cl=35 mL/min/1.73 m2
n3:containedIn
n5:271B5741-363D-11E5-9242-09173F13E4C5 n5:271B573F-363D-11E5-9242-09173F13E4C5 n5:271B5742-363D-11E5-9242-09173F13E4C5 n5:271B5740-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n19:271B575D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n19:271B575F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n19:271B5760-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n19:271B5762-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n19:271B575C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n19:271B575B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n19:271B575E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n19:271B574C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n19:271B5759-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n19:271B575A-363D-11E5-9242-09173F13E4C5